| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Full Paper |
1 Department of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kawaramachi-dori Hirokoji Kamigyo-ku Kyoto, 602-8566, 2 Department of Urology, Kyoto Prefectural University of Medicine and 3 Department of Pathology and Cell Regulation, Kyoto Prefectural University of Medicine, Kyoto, Japan
This study was designed to assess the efficacy of dynamic contrast-enhanced MRI (DCE-MRI), in comparison with power Doppler ultrasound (PDUS), for visualizing prostate cancer. 111 men suspected of having prostate cancer underwent imaging before undergoing octant biopsy. Subsequently, 31 cancer-positive patients were enrolled in this study. DCE-MRI was obtained using a three-dimensional fast-field echo sequence, which assured wide coverage of the prostate gland. The transrectal PDUS were scored according to the degree of power Doppler flow signals. The time intensity curve types for the DCE-MRI and the PDUS scores were compared with the histopathologic results for each region. The time intensity curves were correlated significantly with PDUS scores (p<0.001). Using PDUS, the overall sensitivity, specificity and accuracy of cancer visualization in peripheral zones were 69%, 61% and 66%, respectively. Using DCE-MRI, the corresponding values were 87%, 74% and 82%. In the inner gland, using PDUS, the overall sensitivity, specificity and accuracy were 68%, 94% and 83%, respectively. Using DCE-MRI, the corresponding values were similar (68%, 86% and 78%). DCE-MRI was significantly more sensitive than transrectal PDUS in peripheral zones (p<0.05). In conclusion, both transrectal PDUS and DCE-MRI can be used to demonstrate hypervascularity in many prostate cancers. DCE-MRI was significantly more sensitive than PDUS for visualizing of prostate cancers without loss of specificity in the peripheral zone.
This article has been cited by other articles:
![]() |
I. Ocak, M. Bernardo, G. Metzger, T. Barrett, P. Pinto, P. S. Albert, and P. L. Choyke Dynamic Contrast-Enhanced MRI of Prostate Cancer at 3 T: A Study of Pharmacokinetic Parameters Am. J. Roentgenol., October 1, 2007; 189(4): W192 - W201. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. N. Bloch, E. Furman-Haran, T. H. Helbich, R. E. Lenkinski, H. Degani, C. Kratzik, M. Susani, A. Haitel, S. Jaromi, L. Ngo, et al. Prostate Cancer: Accurate Determination of Extracapsular Extension with High-Spatial-Resolution Dynamic Contrast-enhanced and T2-weighted MR Imaging Initial Results Radiology, October 1, 2007; 245(1): 176 - 185. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Li, K. Sugimura, Y. Kaji, Y. Kitamura, M. Fujii, I. Hara, and M. Tachibana Conventional MRI capabilities in the diagnosis of prostate cancer in the transition zone. Am. J. Roentgenol., March 1, 2006; 186(3): 729 - 742. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Futterer, M. R. Engelbrecht, H. J. Huisman, G. J. Jager, C. A. Hulsbergen-van De Kaa, J. A. Witjes, and J. O. Barentsz Staging Prostate Cancer with Dynamic Contrast-enhanced Endorectal MR Imaging prior to Radical Prostatectomy: Experienced versus Less Experienced Readers Radiology, November 1, 2005; 237(2): 541 - 549. [Abstract] [Full Text] [PDF] |
||||
![]() |
A R Padhani and C M Nutting Why do we need more accurate intraprostatic localization of cancer? Br. J. Radiol., September 1, 2003; 76(909): 585 - 586. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| BJR | DMFR | IMAGING | ALL BIR JOURNALS |